Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial

BACKGROUND AND HYPOTHESIS: Hyperuricaemia and gout are common in chronic kidney disease (CKD). We aimed to assess the effects of sodium-glucose co-transporter-2 (SGLT2) inhibition on uric acid (urate) and gout in patients with CKD. METHODS: The EMPA-KIDNEY trial randomised 6609 patients with CKD (es...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nephrol Dial Transplant
Autors principals: Mayne, Kaitlin J, Sardell, Rebecca J, Staplin, Natalie, Judge, Parminder K, Zhu, Doreen, Sammons, Emily, Cherney, David ZI, Green, Jennifer B., Levin, Adeera, Pontremoli, Roberto, Hauske, Sibylle J., Emberson, Jonathan, Preiss, David, Landray, Martin J, Baigent, Colin, Wanner, Christoph, Haynes, Richard, Herrington, William G
Format: Artigo
Idioma:Inglês
Publicat: 2024
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7616479/
https://ncbi.nlm.nih.gov/pubmed/39277784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfae203
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars